当前位置: X-MOL 学术Lancet Diabetes Endocrinol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Insulin access and affordability in the USA: anticipating the first interchangeable insulin product.
The Lancet Diabetes & Endocrinology ( IF 44.5 ) Pub Date : 2020-03-20 , DOI: 10.1016/s2213-8587(20)30105-4
Jing Luo 1 , Aaron S Kesselheim 2 , Ameet Sarpatwari 2
Affiliation  

An estimated quarter of the 7 million Americans taking insulin have had difficulty paying for their medication. To cope, they have reported using insulin less frequently than prescribed and injecting expired doses, resulting in worse glycaemic control, hospitalisation for diabetic ketoacidosis, and death.

中文翻译:

美国的胰岛素可及性和可负担性:期待第一个可互换的胰岛素产品。

在服用胰岛素的 700 万美国人中,估计有四分之一难以支付药物费用。为了应对,他们报告说使用胰岛素的频率低于规定的剂量并注射过期剂量,导致血糖控制更差、因糖尿病酮症酸中毒住院和死亡。
更新日期:2020-03-21
down
wechat
bug